ESR1 and cancer: Although we did see greater sensitivity in TNBC cell lines compared to other subtypes, we have not tested the sensitivity of ER+ and HER+ cancers in vivo, and we have not determined the mechanism behind the differential sensitivity between subtypes in vitro.